On August 21, 2026, a new clinical trial update was recorded for tirzepatide, an approved compound. The study, titled "An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder," is registered under identifier NCT07693608. This is a Phase 2 trial. Its current status is listed as enrolling by invitation. The trial is designed as open-label, meaning both researchers and participants know which treatment is being given. No results have been posted for this trial at this time. The study focuses on individuals with comorbid obesity and stimulant use disorder, though no outcome data or findings are available in this update. The registration reflects only the trial's design and current enrollment status as of the date listed. Readers interested in ongoing tirzepatide research can follow the trial's progress through its official registry listing. For more background on tirzepatide, including its approved uses and general profile, readers can consult the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07693608"]